Koenig K G, Lindberg J S, Zerwekh J E, Padalino P K, Cushner H M, Copley J B
Department of Internal Medicine, William Beaumont Army Medical Center, El Paso, Texas.
Kidney Int. 1992 Jan;41(1):161-5. doi: 10.1038/ki.1992.22.
Patients with nephrotic syndrome and varying degrees of renal failure, including those on chronic hemo- and peritoneal dialysis, may have low serum concentrations of total 1,25-dihydroxyvitamin D [1,25(OH)2D]. However, it is unknown whether the true activity of 1,25(OH)2D is better reflected by the free 1,25(OH)2D fraction. We measured total 1,25(OH)2D, free 1,25(OH)2D, and vitamin-D-binding protein (DBP) in normal subjects (group A), subjects with moderate renal failure (group B), subjects on hemodialysis (group C), subjects on peritoneal dialysis (group D), and subjects with nephrotic syndrome (group E). The serum concentrations of total and free 1,25(OH)2D decreased with worsening renal function in groups A through C, with a high degree of correlation (r = 0.974, P less than 0.0001). Levels of DBP and the percent free 1,25(OH)2D remained constant in these groups. Patients on peritoneal dialysis and nephrotic patients had lower levels of DBP (203 +/- 14 micrograms/ml and 371 +/- 46 micrograms/ml, respectively) than normal subjects (436 +/- 33 micrograms/ml) and had significantly higher percent free 1,25(OH)2D (0.98 +/- 0.13% and 1.27 +/- 0.14%, respectively) compared to 0.63 +/- 0.03% (P less than 0.05). Thus, the loss of DBP in these patients correlated with a rise in the percent free 1,25(OH)2D. We conclude that levels of total 1,25(OH)2D are an accurate representation of 1,25(OH)2D status in normal subjects, subjects with renal insufficiency without nephrotic syndrome, and hemodialysis patients. In peritoneal dialysis and nephrotic patients, who lose DBP, measurements of free 1,25(OH)2D may be necessary in order to accurately assess 1,25(OH)2D status.
患有肾病综合征和不同程度肾衰竭的患者,包括那些接受慢性血液透析和腹膜透析的患者,其血清总1,25 - 二羟基维生素D [1,25(OH)₂D]浓度可能较低。然而,游离1,25(OH)₂D部分是否能更好地反映1,25(OH)₂D的真实活性尚不清楚。我们测定了正常受试者(A组)、中度肾衰竭受试者(B组)、血液透析受试者(C组)、腹膜透析受试者(D组)和肾病综合征受试者(E组)的总1,25(OH)₂D、游离1,25(OH)₂D和维生素D结合蛋白(DBP)。A组至C组中,随着肾功能恶化,血清总1,25(OH)₂D和游离1,25(OH)₂D浓度下降,且具有高度相关性(r = 0.974,P < 0.0001)。这些组中DBP水平和游离1,25(OH)₂D百分比保持恒定。腹膜透析患者和肾病患者的DBP水平(分别为203±14μg/ml和371±46μg/ml)低于正常受试者(436±33μg/ml),且游离1,25(OH)₂D百分比(分别为0.98±0.13%和1.27±0.14%)显著高于正常受试者的0.63±0.03%(P < 0.05)。因此,这些患者中DBP的丢失与游离1,25(OH)₂D百分比的升高相关。我们得出结论,在正常受试者、无肾病综合征的肾功能不全受试者和血液透析患者中,总1,25(OH)₂D水平能准确反映1,25(OH)₂D状态。在丢失DBP的腹膜透析患者和肾病患者中,可能需要测定游离1,25(OH)₂D以便准确评估1,25(OH)₂D状态。